Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Medroxyprogesterone Acetate). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
SOMA-JECT is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Ovulation suppression: Shake the Medroxyprogesterone Acetate injectable suspension gently just before use so that the dose given is a uniform suspension. The recommended dose is 150 mg/ml of this injectable suspension every three months, given by intramuscular injection into the gluteal or deltoid muscle. The first injection should be given during the first 5 days after the start of a menstrual period; within 5 days after delivery if not breastfeeding; or at or after six weeks after delivery if exclusively breastfeeding. Based on limited experience, some investigators prefer giving a second injection of Medroxyprogesterone Acetate before 90 days to control troublesome bleeding. The third and later injections should be given at separate 90-day intervals. If abnormal bleeding continues, appropriate investigations should be carried out to rule out the possibility of organic disease. Uterine curettage may be needed on rare occasions.
Side Effects
Weight gain, a feeling of heaviness and pain in the abdomen, pain, and anxiety may occur. Amenorrhea, spotting, or excessive bleeding can happen. There may be infection at the injection site, headache, blurring of vision, and pain in the back of the leg. Pregnancy may be delayed after stopping the injectable contraceptive.
Cautions & Contraindications
Warnings & Precautions
Caution is needed if unexpected vaginal bleeding occurs during therapy, in patients with a pre-existing medical condition that might be adversely affected by fluid retention, in patients with a history of treatment for clinical depression, and in diabetic patients. Medroxyprogesterone acetate may decrease the levels of certain endocrine biomarkers, including plasma or urinary steroids (such as cortisol, oestrogen, pregnanediol, progesterone and testosterone), plasma or urinary gonadotrophins (such as LH and FSH), and sex hormone-binding globulin (SHBG).
Contraindications
Known or suspected pregnancy, Undiagnosed vaginal bleeding, Known or suspected malignancy of breast ( when used for ovulation suppression or gynaecology indications), Severe liver dysfunction, Known hypersensitivity to medroxyprogesterone acetate or any component of the drug.